Eli Lilly’s Dermira accuses Perrigo of infringing patents
Pharmaceutical company Eli Lilly’s subsidiary Dermira has accused generic drugmaker Perrigo of infringing eight patents for Qbrexza, a prescription-only cloth towelette approved to treat hyperhidrosis, a condition that causes excessive underarm sweating.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
23 August 2016 AstraZeneca and Eli Lilly have received US Food and Drug Administration fast track designation for the development of a treatment for Alzheimer’s.
16 February 2015 The Canadian government has given a scathing assessment of Eli Lilly’s patenting practices in its formal response to the pharmaceutical company’s CAD $500 million lawsuit against it.